Clinical studies in asthmatics with a new non-extra fine HFA formulation of beclometasone dipropionate (BDP Modulite®)
- 1 August 2002
- journal article
- Published by Elsevier in Respiratory Medicine
- Vol. 96, S17-S27
- https://doi.org/10.1016/s0954-6111(02)80020-8
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellantJournal of Allergy and Clinical Immunology, 1999
- Pharmacokinetics of chlorofluorocarbon and hydrofluoroalkane metered-dose inhaler formulations of beclomethasone dipropionatePublished by Wiley ,1999
- Twenty-eight-day Double-blind Safety Study of an HFA-134a Inhalation Aerosol System in Healthy SubjectsJournal of Pharmacy and Pharmacology, 1996
- HFA-134a (1 ,1, 1, 2-tetrafluoroethane): lack of oncogenicity in rodents after inhalationHuman & Experimental Toxicology, 1995
- An overview of the toxicology of HFA-134a (1,1,1,2-tetrafluoroethane)Human & Experimental Toxicology, 1995
- CFCs, their Replacements, and the Ozone LayerJournal of Aerosol Medicine, 1995
- The Montreal Protocol and Essential Use ExemptionsJournal of Aerosol Medicine, 1995
- Approaches and Challenges to Use Freon Propellant ReplacementsAerosol Science and Technology, 1995
- Safety of PropellantsJournal of Aerosol Medicine, 1995
- Beclomethasone Dipropionate A Reappraisal of its Pharmacodynamic Properties and Therapeutic Efficacy After a Decade of Use in Asthma and RhinitisDrugs, 1984